From Hazelden Betty Ford <[email protected]>
Subject New Study: Opioid Addiction Treatment
Date October 22, 2019 10:41 AM
  Links have been removed from this email. Learn more in the FAQ.
  Links have been removed from this email. Learn more in the FAQ.
View Online [link removed]

In Fight to End Nation's Opioid Crisis, a New Treatment Approach Emerges

Seven years after the industry-leading Hazelden Betty Ford Foundation overhauled its approach to treating opioid addiction, research shows its new model is producing successful outcomes.

The naturalistic, prospective study followed 253 adult patients with opioid use disorder who were admitted to Hazelden Betty Ford's residential treatment facility in Center City, Minnesota, between June 2013 and June 2017. Patients participating in COR-12™ received opioid-specific therapy, education and case management; were given the option of Suboxone, Vivitrol or no medication; and participated in the rest of Hazelden Betty Ford's treatment model, which utilizes the best evidence-based clinical practices and systematically connects patients to peer support and other recovery resources.

Learn more about the peer-reviewed study and research outcomes at [link removed]

You are receiving this message because you've registered or accepted our invitation to receive email from the Hazelden Betty Ford Foundation.

Preferences [link removed] | Unsubscribe [link removed]

[link removed]

[link removed]

[link removed]

[link removed]

[link removed]

[link removed]

[link removed]

Hazelden Betty Ford Foundation
15251 Pleasant Valley Rd.
PO Box 11 RW19
Center City, MN 55012-0011

6790-19
Screenshot of the email generated on import

Message Analysis